CTS CORP reported second-quarter 2026 results with revenue of $144.78M, up 7% from $135.31M a year earlier, and diluted earnings per share of $0.66 versus $0.62 in the prior-year quarter; net income was $19.16M compared with $18.53M in Q2 2025.
Financial Highlights
- Revenue was $144.78M for Q2 2026, compared with $135.31M in the year-ago quarter; YoY change 7.0%.
- Net income was $19.16M for Q2 2026, compared with $18.53M in the year-ago quarter; YoY change 3.4%.
- Diluted EPS was $0.66 for Q2 2026, compared with $0.62 in the year-ago quarter.
Business Highlights
- Net sales growth of 7.0% in Q2 and 8.8% year-to-date was driven by strength in medical and industrial end markets.
- A shift in channel and mix reduced reliance on transportation, with diversified end-market sales up roughly 14–16%.
- Gross margin improved to about 41.5% in Q2 from 38.7%, supported by favorable mix and operational gains.
- SG&A increased due to higher incentive compensation while R&D decreased partly because of a $1.6M customer reimbursement.
- Leadership change effective July 6, 2026: the CEO transition progressed with the new CEO promoted and the former CEO moving to Executive Chair.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.